192 related articles for article (PubMed ID: 22590653)
1. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.
Jiang W; Jin G; Ma D; Wang F; Fu T; Chen X; Chen X; Jia K; Marikar FM; Hua Z
PLoS One; 2012; 7(5):e37132. PubMed ID: 22590653
[TBL] [Abstract][Full Text] [Related]
2. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
Yokoyama Y; Ramakrishnan S
Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188
[TBL] [Abstract][Full Text] [Related]
3. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
[TBL] [Abstract][Full Text] [Related]
4. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.
Pasqualini R; Koivunen E; Kain R; Lahdenranta J; Sakamoto M; Stryhn A; Ashmun RA; Shapiro LH; Arap W; Ruoslahti E
Cancer Res; 2000 Feb; 60(3):722-7. PubMed ID: 10676659
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of RGD tumour-homing-peptide-modified plasminogen K5.
Wang Y; Guo Z; Ge Q; Wang E; Zhang X; Jin G
Biotechnol Appl Biochem; 2010 Sep; 57(1):17-24. PubMed ID: 20718711
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1α pathway.
Cai WB; Zhang Y; Cheng R; Wang Z; Fang SH; Xu ZM; Yang X; Yang ZH; Ma JX; Shao CK; Gao GQ
PLoS One; 2012; 7(12):e53152. PubMed ID: 23300882
[TBL] [Abstract][Full Text] [Related]
7. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
8. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
[TBL] [Abstract][Full Text] [Related]
9. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
10. NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity.
Corti A; Gasparri AM; Sacchi A; Colombo B; Monieri M; Rrapaj E; Ferreri AJM; Curnis F
Mol Pharm; 2020 Oct; 17(10):3813-3824. PubMed ID: 32805112
[TBL] [Abstract][Full Text] [Related]
11. In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature.
Ma W; Li G; Wang J; Yang W; Zhang Y; Conti PS; Chen K
Amino Acids; 2014 Dec; 46(12):2721-32. PubMed ID: 25182731
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
[TBL] [Abstract][Full Text] [Related]
13. p22 is a novel plasminogen fragment with antiangiogenic activity.
Kwon M; Yoon CS; Fitzpatrick S; Kassam G; Graham KS; Young MK; Waisman DM
Biochemistry; 2001 Nov; 40(44):13246-53. PubMed ID: 11683633
[TBL] [Abstract][Full Text] [Related]
14. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
[TBL] [Abstract][Full Text] [Related]
15. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of angiogenesis with a recombinant CTT peptide-endostatin mimic-kringle 5 protein.
Wang H; Yang Z; Gu J
Mol Cancer Ther; 2014 Nov; 13(11):2674-87. PubMed ID: 25127900
[TBL] [Abstract][Full Text] [Related]
17. Isolation and purification of recombinant human plasminogen Kringle 5 by liquid chromatography and ammonium sulfate salting-out.
Bian L; Ji X; Hu W
Biomed Chromatogr; 2014 Jul; 28(7):957-65. PubMed ID: 24311387
[TBL] [Abstract][Full Text] [Related]
18. Characterization and biological activities of recombinant human plasminogen kringle 1-3 produced in Escherichia coli.
You WK; So SH; Sohn YD; Lee H; Park DH; Chung SI; Chung KH
Protein Expr Purif; 2004 Jul; 36(1):1-10. PubMed ID: 15177278
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of Action of the Tumor Vessel Targeting Agent NGR-hTNF: Role of Both NGR Peptide and hTNF in Cell Binding and Signaling.
Valentinis B; Porcellini S; Asperti C; Cota M; Zhou D; Di Matteo P; Garau G; Zucchelli C; Avanzi NR; Rizzardi GP; Degano M; Musco G; Traversari C
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31547231
[TBL] [Abstract][Full Text] [Related]
20. NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature.
Zou M; Zhang L; Xie Y; Xu W
Anticancer Agents Med Chem; 2012 Mar; 12(3):239-46. PubMed ID: 22263803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
